tiprankstipranks
Akero Therapeutics Advances in MASH Treatment Trials
PremiumCompany AnnouncementsAkero Therapeutics Advances in MASH Treatment Trials
2M ago
Is AKRO a Buy, Before Earnings?
Premium
Pre-Earnings
Is AKRO a Buy, Before Earnings?
2M ago
Akero Therapeutics reports Q3 EPS ($1.05), consensus (90c)
Premium
The Fly
Akero Therapeutics reports Q3 EPS ($1.05), consensus (90c)
2M ago
Akero Therapeutics sees cash runway into 2H27
PremiumThe FlyAkero Therapeutics sees cash runway into 2H27
5M ago
Akero Therapeutics reports Q2 EPS (81c), consensus (90c)
Premium
The Fly
Akero Therapeutics reports Q2 EPS (81c), consensus (90c)
5M ago
Class Action Lawsuit against Akero Therapeutics, Inc. (NASDAQ:AKRO)
Premium
Market News
Class Action Lawsuit against Akero Therapeutics, Inc. (NASDAQ:AKRO)
7M ago
Akero Therapeutics price target lowered to $38 from $50 at Evercore ISI
PremiumThe FlyAkero Therapeutics price target lowered to $38 from $50 at Evercore ISI
8M ago
Akero Therapeutics price target lowered to $56 from $59 at Canaccord
Premium
The Fly
Akero Therapeutics price target lowered to $56 from $59 at Canaccord
8M ago
Akero Therapeutics files automatic mixed securities shelf
Premium
The Fly
Akero Therapeutics files automatic mixed securities shelf
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100